New hope for lymphoma patients at high risk of cancer returning

NCT ID NCT03463057

Summary

This study tests whether adding the immunotherapy drug atezolizumab after standard chemotherapy can help prevent cancer from returning in patients with high-risk diffuse large B-cell lymphoma. The trial enrolled 109 adults who had responded well to initial treatment but remain at high risk of relapse. Researchers want to see if this additional treatment improves survival by targeting any remaining cancer cells the initial therapy might have missed.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • BE-Antwerpen Edegem-UZA

    Antwerp, Belgium

  • BE-Antwerpen-ZNASTUIVENBERG

    Antwerp, Belgium

  • BE-Brugge-AZBRUGGE

    Bruges, Belgium

  • BE-Leuven-UZLEUVEN

    Leuven, Belgium

  • BE-Roeselare-AZDELTA

    Roeselare, Belgium

  • NL-Amersfoort-MEANDERMC

    Amersfoort, Netherlands

  • NL-Amsterdam-OLVG

    Amsterdam, Netherlands

  • NL-Amsterdam-VUMC

    Amsterdam, Netherlands

  • NL-Apeldoorn-GELREAPELDOORN

    Apeldoorn, Netherlands

  • NL-Breda-AMPHIA

    Breda, Netherlands

  • NL-Delft-RDGG

    Delft, Netherlands

  • NL-Den Bosch-JBZ

    's-Hertogenbosch, Netherlands

  • NL-Den Haag-HAGA

    The Hague, Netherlands

  • NL-Dordrecht-ASZ

    Dordrecht, Netherlands

  • NL-Ede-ZGV

    Ede, Netherlands

  • NL-Eindhoven-CATHARINA

    Eindhoven, Netherlands

  • NL-Eindhoven-MAXIMAMC

    Eindhoven, Netherlands

  • NL-Enschede-MST

    Enschede, Netherlands

  • NL-Groningen-UMCG

    Groningen, Netherlands

  • NL-Hilversum-TERGOOI

    Hilversum, Netherlands

  • NL-Hoofddorp-SPAARNEGASTHUIS

    Hoofddorp, Netherlands

  • NL-Leeuwarden-MCL

    Leeuwarden, Netherlands

  • NL-Leiden-LUMC

    Leiden, Netherlands

  • NL-Maastricht-MUMC

    Maastricht, Netherlands

  • NL-Nieuwegein-ANTONIUS

    Nieuwegein, Netherlands

  • NL-Nijmegen-CWZ

    Nijmegen, Netherlands

  • NL-Rotterdam-ERASMUSMC

    Rotterdam, Netherlands

  • NL-Rotterdam-MAASSTADZIEKENHUIS

    Rotterdam, Netherlands

  • NL-Sittard-Geleen-ZUYDERLAND

    Sittard, Netherlands

  • NL-Tilburg-ETZ

    Tilburg, Netherlands

  • NL-Utrecht-UMCUTRECHT

    Utrecht, Netherlands

  • NL-Zwolle-ISALA

    Zwolle, Netherlands

Conditions

Explore the condition pages connected to this study.